High-mobility group box 1 has a prognostic role and contributes to epithelial mesenchymal transition in human hepatocellular carcinoma

Molecular Medicine Reports

Volumn 12, Issue 4, 2015, Pages 5997-6004

  Liu, Zhikui ^a   Dou, Changwei ^a   Wang, Yufeng ^a   Jia, Yuli ^a   Li, Qing ^a   Zheng, Xin ^a   Yao, Yingmin ^a   Liu, Qingguang ^a   Song, Tao ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Epithelial mesenchymal transition; Hepatocellular carcinoma; High mobility group box 1; Invasion; Metastasis; Prognosis

Indexed keywords

FIBRONECTIN; HIGH MOBILITY GROUP B1 PROTEIN; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; SMALL INTERFERING RNA; UVOMORULIN; VIMENTIN; HMGB1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; DISEASE FREE SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE CONTRAST MICROSCOPY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING; CARCINOMA, HEPATOCELLULAR; CELL MOTION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PROGNOSIS; TUMOR CELL LINE;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE-FREE SURVIVAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGB1 PROTEIN; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84940532833     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4182     Document Type: Article

References (25)

1. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007.
2. Smith MW, Yue ZN, Korth MJ, Do HA, Boix L, Fausto N, Bruix J, Carithers RL Jr and Katze MG: Hepatitis C virus and liver disease: Global transcriptional profling and Identification of potential markers. Hepatology 38: 1458-1467, 2003.
3. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, et al: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100: 698-711, 2008.
4. Talwalkar JA and Gores GJ: Diagnosis and staging of hepatocellular carcinoma. Gastroenterology 127 (5 Suppl 1): S126-S132, 2004.
5. Kim DH and Rossi JJ: Strategies for silencing human disease using RNA interference. Nat Rev Genet 8: 173-184, 2007
6. Gartel AL and Kandel ES: RNA interference in cancer. Biomol Eng 23: 17-34, 2006.
7. Castanotto D and Rossi JJ: The promises and pitfalls of RNA-interference-based therapeutics. Nature 457: 426-433, 2009.
8. Javaherian K, Liu JF and Wang JC: Nonhistone proteins HMG1 and HMG2 change the DNA helical structure. Science 199: 1345-1346, 1978.
9. Lotze MT and Tracey KJ: High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 5: 331-342, 2005.
10. Sims GP, Rowe DC, Rietdijk ST, Herbst R and Coyle AJ: HMGB1 and RAGE in infammation and cancer. Annu Rev Immunol 28: 367-388, 2010.
11. Tang D, Kang R, Zeh HJ III and Lotze MT: High-mobility group box 1 and cancer. Biochim Biophys Acta 1799: 131-140, 2010.
12. Kostova N, Zlateva S, Ugrinova I and Pasheva E The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem 337: 251-258, 2010.
13. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, Yamada S, Maruyama I, Banerjee A, et al: High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 290: C917-C924, 2006.
14. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ and Yang H: HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26: 174-179, 2006.
15. Wolfson RK, Chiang ET and Garcia JG: HMGB1 induces human lung endothelial cell cytoskeletal rearrangement and barrier disruption. Microvasc Res 81: 189-197, 2011.
16. Larocca C, Cohen JR, Fernando RI, Huang B, Hamilton DH and Palena C: An autocrine loop between TGF-β1 and the transcription factor brachyury controls the transition of human carcinoma cells into a mesenchymal phenotype. Mol Cancer Ther 12: 1805-1815, 2013.
17. Yang JD, Harmsen WS, Slettedahl SW, Chaiteerakij R, Enders FT, Therneau TM, Orsini L, Kim WR and Roberts LR: Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol 9: 617-623 e1, 2011.
18. El-Nahas AM: Plasticity of kidney cells: Role in kidney remodeling and scarring. Kidney Int 64: 1553-1563, 2003.
19. Sato M, Shames DS and Hasegawa Y: Emerging evidence of epithelial-to-mesenchymal transition in lung carcinogenesis. Respirology 17: 1048-1059, 2012.
20. Liu Z, Dou C, Jia Y, Li Q, Zheng X, Yai Y, Liu Q and Song T: RIG-I suppresses the migration and invasion of hepatocellular carcinoma cells by regulating MMP9 Int J Oncol 46: 1710-1720, 2015
21. Rudmik LR and Magliocco AM: Molecular mechanisms of hepatic metastasis in colorectal cancer. J Surg Oncol 92: 347-359, 2005
22. Kumar S and Weaver VM: Mechanics, malignancy and metastasis: The force journey of a tumor cell. Cancer Metastasis Rev 28: 113-127, 2009
23. Naghavi MH, Nowak P, Andersson J, Sönnerborg A, Yang H, Tracey KJ and Vahlne A: Intracellular high mobility group B1 protein (HMGB1) represses HIV-1 LTR-directed transcription in a promoter-and cell-specifc manner. Virology 314: 179-189, 2003.
24. Ueda M, Takahashi Y, Shinden Y, Sakimura S, Hirata H, Uchi R, Takano Y, Kurashige J, Iguchi T, Eguchi H, et al: Prognostic signifcance of high mobility group box 1 (HMGB1) expression in patients with colorectal cancer. Anticancer Res 34: 5357-5362, 2014
25. Li LC, Gao J and Li J: Emerging role of HMGB1 in fbrotic diseases. J Cell Mol Med 18: 2331-2339, 2014